1. 2019
  2. The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

    Faict, S., Oudaert, I., D'Auria, L., Dehairs, J., Maes, K., Vlummens, P., Veirman, K. D., Bruyne, E. D., Fostier, K., Broek, I. V., Schots, R., Vanderkerken, K., Swinnen, J. V. & Menu, E., 20 Nov 2019, In : Cancers. 11, 12, 1823.

    Research output: Contribution to journalArticle

  3. 2015
  4. Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma

    Decoster, L., Vande Broek, I., Neyns, B., Majois, F., Baurain, J. F., Rottey, S., Rorive, A., Anckaert, E., DE Mey, J., DE Brakeleer, S. & DE Grève, J., Dec 2015, In : Anticancer Research. 35, 12, p. 6893-6899 7 p.

    Research output: Contribution to journalArticle

  5. 2014
  6. IMWG consensus on risk stratification in multiple myeloma

    Chng, W., Dispenzieri, A., Chim, C. S., Schots, H., Van Camp, B., Van Riet, I., Vande Broek, I. & Vanderkerken, K., 5 Feb 2014, In : Leukemia. 28, p. 269-277

    Research output: Contribution to journalArticle

  7. 2013
  8. Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo

    Xu, S., De Veirman, K., Evans, H. R., Santini, G., Vande Broek, I., Leleu, X., De Becker, A., Van Camp, B., Croucher, P. I., Vanderkerken, K. & Van Riet, I., 8 Apr 2013, In : Acta Pharmacol Sin.. 34, 5, p. 699-709

    Research output: Contribution to journalArticle

  9. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Fernández De Larrea, C., Kyle, R., Durie, B., Ludwig, H., Usmani, S., Vesole, D., San Miguel, J. F., Sezer, O., Sonneveld, P., Kumar, S., Mahindra, A., Anderson, K., Schots, H., Van Camp, B., Van Riet, I., Vande Broek, I. & Vanderkerken, K., 1 Apr 2013, In : Leukemia. 27, 4, p. 780-791

    Research output: Contribution to journalArticle

  10. Epigenetic modulation of myeloma within its bone marrow microenvironment

    De Bruyne, E., Maes, K., Deleu, S., Van Valckenborgh, E., Menu, E., Vande Broek, I., Fraczek, J., Van Grunsven, L., Rogiers, V., Jernberg-Wiklund, H. & Vanderkerken, K., 2013, Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Munshi, N. C. & Anderson, K. C. (eds.). New York: Springer, Vol. 1. p. 255-282 28 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter

  11. 2012
  12. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

    Kumar, S., Lee, J., Lahuerta, J., Morgan, G., Richardson, P., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., Leleu, X., Van Camp, B., Van Riet, I., Vande Broek, I. & Vanderkerken, K., 2012, In : Leukemia. 26, 1, p. 149-157

    Research output: Contribution to journalArticle

  13. 2011
  14. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay.

    Vercammen, M., Meirlaen, P., Broodtaerts, L., Vande Broek, I. & Bossuyt, X., 29 Jun 2011, In : Clinica Chimica Acta. 412, 2011, p. 1798-1804 6 p.

    Research output: Contribution to journalArticle

Previous 1 2 3 4 5 6 7 Next

ID: 123739